Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...

The FDA should have more big news for Vertex only a few weeks later. It expects to announce an approval decision on ...

NEW YORK -- U.S. pharmaceutical company Moderna could have a vaccine to treat melanoma, a form of skin cancer, on the market ...

Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer ...

Moderna jolted investors by pushing back its profitability forecast two years, to 2028, and announcing a $1.1 billion cut in R&D spending.

sending the drugmaker's stock price soaring while denting high-flying shares of vaccine companies and makers of other coronavirus therapies. Pfizer and its rivals, including U.S.-based Merck & Co ...

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

AstraZeneca recorded a big jump in revenue on Thursday as it begins to take a profit from its coronavirus vaccine for the first time. Positive clinical trial results for Merck & Co's experimental ...

Bolstered by Covid-19 revenues ... with treatments such as Keytruda could prove crucial to realising vaccines’ potential. Merck’s drug is the most successful of a wave of immunotherapies ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...